CMN 20 de Noviembre ISSSTE
CMN 20 de Noviembre ISSSTE
Perez-Razo J.C.,CMN 20 de Noviembre ISSSTE |
Cano-Martinez L.J.,CMN 20 de Noviembre ISSSTE |
Vargas Alarcon G.,Grupo Mexico |
Canizales-Quinteros S.,National Autonomous University of Mexico |
And 9 more authors.
Circulation: Cardiovascular Genetics | Year: 2015
Background - Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) have been associated with diastolic blood pressure, hypertension, and other cardiovascular diseases; however, results of these studies are still controversial. In this study, we sought to determine whether 2 functional variants (rs1801133 and rs13306560) within the MTHFR are associated with hypertension in Mexican-Mestizos. Methods and Results - We performed a case-control study with 1214 subjects including adults and children to test for the association of both single nucleotide polymorphisms with essential hypertension. The adult group included 764 participants (372 patients and 391 controls) and the group of children included 418 participants (209 patients and 209 controls). rs13306560 was associated with essential hypertension in adults (odds ratio, 4.281; 95% confidence interval, 1.841-9.955; P=0.0003) with a statistical power >0.8. In children, none of the polymorphisms was associated with essential hypertension. In addition, we assessed the effect of the rs13306560 polymorphism on the MTHFR promoter region by means of luciferase reporter gene assays using human umbilical vein endothelial cells. Cells transfected with the pMTHFRaLUC construct showed an ≈25% reduction in luciferase activity (P=0.003). Furthermore, the promoter activity was reduced considerably by in vitro methylation of CpG sequences. Conclusions - Our data suggest that the rs13306560 polymorphism of the MTHFR may be part of the observed hypertension process in Mexican-Mestizo populations, but further studies are warranted. In addition, the allele A of the rs13306560 polymorphism as well as the in vitro methylation of CpGs reduced the promoter activity of the MTHFR regulatory region. © 2015 American Heart Association, Inc.
Reduction in requirements of oral calcium and 1-25 dihydroxy vitamin D in patients with post-surgical hypoparathyroidism treated with teriparatide (PTH1-34)) [Reducción en los requerimientos de calcio oral y de 1-25 dihidroxi-vitamina D en pacientes con hipoparatiroidismo posquirúrgico tratados con teriparatida (Pth1-34)]
Gutierrez-Cerecedo L.E.,Hospital Regional 1O Of Octubre Issste |
Vergara-Lopez A.,CMN 20 de Noviembre ISSSTE |
Rosas-Barrientos J.V.,Hospital Regional 1O Of Octubre Issste |
Guillen-Gonzalez M.A.,CMN 20 de Noviembre ISSSTE
Gaceta Medica de Mexico | Year: 2016
The objective of the study is to evaluate the effect of daily administration of recombinant parathyroid hormone (PTH1-34), 20 µg, on serum calcium concentrations (Cas), and the requirements of oral calcium and calcitriol in patients with hypoparathyroidism. It is a prospective, longitudinal study, analytical, with intervention, in patients treated with high doses of calcium (> 7 g/day), with symptoms of hypocalcemia and/or intolerant to treatment. Serum levels of phosphorus (Ps) and Cas, urinary calcium excretion, oral doses of calcitriol and calcium were compared before and after administration of teriparatide, for three months on average, in patients with post-surgical hypoparathyroidism. We studied 16 patients with oral elemental calcium requirements of 22.5 ± 16 g/day of calcitriol 0.79 ± 0.4 µg/day. Cas at baseline was 7.6 ± 1.2 and Ps 5.4 ± 0.76 mg/dl. After administration of teriparatide, Cas was 9.0 ± 0.69 mg/dl (p = 0.007) and Ps of 4.5 ± 0.87 mg/dl (p = 0.003). Doses of calcium and calcitriol showed a statistically significant reduction (p = 0.0001 and 0.001, respectively). We conclude that use of recombinant parathyroid hormone can normalize Cas and Ps, with reduction in oral calcium and calcitriol requirements. © 2016, Academia Nacional de Medicina. All rights reserved.